1. In Vivo
  2. >>Innovation

A Little Light Shines On Interventional Neuroradiologists

The young and hybrid specialty of interventional neuroradiology is pushing to assume a leadership role in treatment of acute neurovascular disease. Interventional neuroradiologists are the endovascular experts who attempt to do for the brain what interventional cardiologists do for the heart. Their success has ijmplications for device companies, which are eyeing the field but hesitant to commit heavily to it because of concerns about market size and infrastructure.

Ever since UK investigators prematurely stopped enrollment in the high-profile ISAT trial in May 2002, interventional neuroradiologists (INRs) have been on a high. The first major randomized study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms favored coils so strongly that the study's principal investigators decided continuing it would be unfair to surgical patients. The results have already changed treatment patterns in some parts of Europe.

Nearly a year later, the American Stroke Association, at its important annual scientific meeting in February, devoted a day of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.